Vaxcyte

vaxcyte.com

Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California, focused on eliminating bacterial infections through advanced vaccine development. The company utilizes its proprietary Xpress CF™ cell-free protein synthesis platform to engineer high-fidelity vaccines, including its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) that has received FDA Breakthrough Therapy designation. Vaxcyte aims to improve upon existing vaccines by addressing antibiotic resistance and expanding coverage against invasive pneumococcal disease. The pipeline includes VAX-31, a broader-spectrum PCV candidate, and other vaccines targeting Group A Strep, periodontitis, and Shigella, positioning Vaxcyte as a leader in the next generation of vaccine innovation.